University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Kole Roybal, PhD

Kole Roybal, PhD

Assistant Professor, Department of Microbiology and Immunology, UCSF

Cancer Center Program Memberships

Cancer Immunology

Research Summary

In the Roybal Lab we harness the tools of synthetic and chemical biology to enhance the therapeutic potential of engineered immune cells. We take a comprehensive approach to cellular engineering by developing new synthetic receptors, signal transduction cascades, and cellular response programs to enhance the safety and effectiveness of adoptive cell therapies. We also study the logic of natural cellular signaling systems, and the underlying principles of cellular communication and collective cell behavior during an immune response.

Education

Austin College, B.A., 05/2005, Biology
UT Southwestern Medical Center at Dallas, Ph.D., 01/2013, Molecular Immunology


Professional Experience

  • 2013-2017
    Jane Coffin Fund Fellow, Dept. of Cell and Molecular Pharmacology, UCSF
  • 2017-present
    Assistant Professor, Dept. of Microbiology and Immunology, UCSF
  • 2017-present
    Investigator, Parker Institute for Cancer Immunotherapy
  • 2017-present
    Investigator, Chan Zuckerberg Biohub

Honors & Awards

  • 2007
    Ruth L. Kirschstein National Research Service Award, National Institutes of Health
  • 2011
    Eliot Golding’s Award for thesis in Immunology, UT Southwestern Medical Center
  • 2012
    Dean’s Award for Academic and Research Excellence, UT Southwestern Medical Center
  • 2016
    Keynote Address at the UAB Comprehensive Cancer Center Retreat
  • 2017
    Named to first cohort of Chan Zuckerberg Biohub Investigators

Selected Publications

  1. Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv. 2020 Jul 14; 4(13):2899-2911.
    View on PubMed
  2. Landgraf KE, Williams SR, Steiger D, Gebhart D, Lok S, Martin DW, Roybal KT, Kim KC. convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting. Commun Biol. 2020 Jun 09; 3(1):296.
    View on PubMed
  3. Roth TL, Li PJ, Blaeschke F, Nies JF, Apathy R, Mowery C, Yu R, Nguyen MLT, Lee Y, Truong A, Hiatt J, Wu D, Nguyen DN, Goodman D, Bluestone JA, Ye CJ, Roybal K, Shifrut E, Marson A. Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies. Cell. 2020 Apr 30; 181(3):728-744.e21.
    View on PubMed
  4. Payal Watchmaker, Joseph Choe, Diego Carrera, Ryan Gilbert, Wei Yu, Kira Downey, Kole Roybal, Wendell Lim, Hideho Okada. IMMU-21. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION. Neuro-Oncology. 2019 Nov 11; 21(Supplement_6):vi123-vi123.
    View on PubMed
  5. Hyrenius-Wittsten A, Roybal KT. Paving New Roads for CARs. Trends Cancer. 2019 10; 5(10):583-592.
    View on PubMed
  6. Azimi CS, Tang Q, Roybal KT, Bluestone JA. NextGen cell-based immunotherapies in cancer and other immune disorders. Curr Opin Immunol. 2019 08; 59:79-87.
    View on PubMed
  7. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. Clonal Deletion of Tumor-Specific T Cells by Interferon-? Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity. 2019 02 19; 50(2):477-492.e8.
    View on PubMed
  8. Shalini T. Low-Nam, Jenny JY Lin, Darren B. McAffee, Steven A. Alvarez, Scott D. Hansen, Kole T. Roybal, Jay T. Groves. Beyond the TCR, Antigen Discrimination in T Cells Continues in the LAT:GRB2:SOS Protein Condensate. Biophysical Journal. 2019 Feb 1; 116(3):530a.
    View on PubMed
  9. Poornima Ramkumar, Jaime Leong, Meghan Seyler, Stratton J Georgoulis, Axel Hyrenius Wittsten, Priya Choudhry, Kole Roybal, Arun P Wiita, Martin Kampmann. Identifying Factors in Multiple Myeloma Controlling Response to B-Cell Maturation Antigen (BCMA)-Targeted Immunotherapy Using CRISPR-Based Functional Genomics. Blood. 2018 Nov 29; 132(Supplement 1):1926-1926.
    View on PubMed
  10. Payal Watchmaker, Joseph Choe, Diego Carrera, Kira Downey, Maryam Shahin, Kole Roybal, Wendell Lim, Hideho Okada. IMMU-57. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION. Neuro-Oncology. 2018 Nov 5; 20(suppl_6):vi134-vi134.
    View on PubMed
  11. Roybal KT. Refining cell therapy. Science. 2018 Mar 09; 359(6380):1112-1113.
    View on PubMed
  12. Roybal KT, Lim WA. Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities. Annu Rev Immunol. 2017 04 26; 35:229-253.
    View on PubMed
  13. Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, Marson A. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017 04 07; 7(1):737.
    View on PubMed
  14. Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, Walker WJ, McNally KA, Lim WA. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell. 2016 Oct 06; 167(2):419-432.e16.
    View on PubMed
  15. Roybal KT, Buck TE, Ruan X, Cho BH, Clark DJ, Ambler R, Tunbridge HM, Zhang J, Verkade P, Wülfing C, Murphy RF. Computational spatiotemporal analysis identifies WAVE2 and cofilin as joint regulators of costimulation-mediated T cell actin dynamics. Sci Signal. 2016 Apr 19; 9(424):rs3.
    View on PubMed
  16. Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, Lim WA. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell. 2016 Feb 11; 164(4):780-91.
    View on PubMed
  17. Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, Lim WA. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Cell. 2016 Feb 11; 164(4):770-9.
    View on PubMed
  18. C. Wülfing, K.T. Roybal. Cellular Structures Controlling T Cell Signaling in Time and Space. Encyclopedia of Cell Biology. 2016 Jan 1; 677-686.
    View on PubMed
  19. Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015 Oct 16; 350(6258):aab4077.
    View on PubMed
  20. Roybal KT, Mace EM, Mantell JM, Verkade P, Orange JS, Wülfing C. Early Signaling in Primary T Cells Activated by Antigen Presenting Cells Is Associated with a Deep and Transient Lamellal Actin Network. PLoS One. 2015; 10(8):e0133299.
    View on PubMed

Go to UCSF Profiles, powered by CTSI